$18.86
0.63% yesterday
Nasdaq, Nov 12, 10:00 pm CET
ISIN
US05455M1009
Symbol
TECX

AVROBIO Inc Stock price

$18.86
+2.77 17.22% 1M
-1.85 8.93% 6M
-27.31 59.15% YTD
-28.89 60.50% 1Y
+9.62 104.19% 3Y
-173.14 90.18% 5Y
-355.54 94.96% 10Y
-355.54 94.96% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
-0.12 0.63%
ISIN
US05455M1009
Symbol
TECX
Industry

Key metrics

Basic
Market capitalization
$353.0m
Enterprise Value
$66.3m
Net debt
positive
Cash
$287.4m
Shares outstanding
18.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
92.1%
Return on Equity
-41.2%
ROCE
-26.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-73.1m | $-80.6m
EBIT
$-74.3m | $-88.0m
Net Income
$-66.0m | $-79.6m
Free Cash Flow
$-64.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-29.4% | -41.8%
EBIT
-30.3% | -51.8%
Net Income
-13.3% | -37.3%
Free Cash Flow
25.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.5
FCF per Share
$-3.4
Short interest
45.4%
Employees
-
Rev per Employee
-
Show more

Is AVROBIO Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

AVROBIO Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a AVROBIO Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a AVROBIO Inc forecast:

Buy
93%
Hold
7%

Financial data from AVROBIO Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
14% 14%
-
- Research and Development Expense 53 53
44% 44%
-
-73 -73
29% 29%
-
- Depreciation and Amortization 1.20 1.20
126% 126%
-
EBIT (Operating Income) EBIT -74 -74
30% 30%
-
Net Profit -66 -66
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about AVROBIO Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVROBIO Inc Stock News

Neutral
Seeking Alpha
13 days ago
Tectonic Therapeutic, Inc. ( TECX ) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients October 29, 2025 4:30 PM EDT Company Participants Alise Reicin - President, CEO, Secretary & Director Marcella Ruddy - Chief Medical Officer Conference Call Participants Frances Dovell - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division...
Neutral
GlobeNewsWire
15 days ago
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose of TX45 was well tolerated in this patient popula...
Neutral
GlobeNewsWire
3 months ago
WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking ...
More AVROBIO Inc News

Company Profile

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alise Reicin
Founded 2015
Website tectonictx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today